FDA 483 - Finish Line Horse Products, Inc. - September 16, 2022

Finish Line, Inc., an animal drug manufacturer in Bensenville, IL, was cited for five significant observations during an FDA inspection. The findings indicate serious deficiencies across multiple GMP areas, including facility sanitation, material segregation, quality control documentation, labeling control, and product stability testing. These issues suggest a systemic lack of adherence to good manufacturing practices, posing potential risks to product quality and integrity.